Monday 13th June 2022 |
Text too small? |
Comvita now forecasts that its full year reported EBITDA is expected to be in a range of $28.5M –$30.0M (previous guidance operating EBITDA $27M – $30M). For clarity, this new range includes Comvita absorbing the impact of previously disclosed one off M&A costs of circa $1M. Comvita is also forecasting double digit growth in Net Profit after Tax for the full year versus the prior corresponding period.
Commenting David Banfield “I am delighted with the momentum that we are experiencing in the business and the ongoing resilience of our focused business model. Consumers continue to choose premium solutions from Comvita as a key part of helping to build natural immunity. This updated guidance is particularly encouraging given the material disruption to offline trade in mainland China through the last quarter and is testament to the quality of our team around the world and at home in Aotearoa, New Zealand”.
Ends.
Comvita full year guidance update – FY22
No comments yet
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors
December 19th Morning Report
RAD - Radius Care Announces On-market Share Buyback Programme
MCY - New wind farm propels MCY renewables commitment to $1b